Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | TEK | Q02763 | 3/20 | 0.46 |
| ▸ | KIT | P10721 | 11/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 9/20 | 0.45 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20133506 | 0.89 | ABL1 (0.51) | ABL1ROR1LCKKDRTEK | |
| SCHEMBL29483761 | 0.86 | KIT (0.45) | ABL1LCKKDRTEKKIT | |
| SCHEMBL18247795 | 0.86 | KIT (0.45) | ABL1LCKKDRTEKKIT | |
| SCHEMBL4063551 | 0.85 | ABL1 (0.51) | ABL1ROR1LCKKDRTEK | |
| SCHEMBL18247796 | 0.85 | ABL1 (0.45) | ABL1ROR1LCKKDRTEK | |
| SCHEMBL21678130 | 0.81 | LCK (0.46) | ABL1ROR1LCKKDRTEK | |
| SCHEMBL18257238 | 0.79 | ABL1 (0.59) | ABL1KITDDR1DDR2 | |
| SCHEMBL18257151 | 0.79 | ABL1 (0.68) | ABL1ROR1LCKKDRTEK | |
| SCHEMBL4245285 | 0.79 | LCK (0.41) | ABL1LCKKDRTEKKIT | |
| SCHEMBL4245130 | 0.79 | SORT1 (0.46) | ABL1ROR1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3297991-B1 | NOVEL AMIDOHETEROARYL AROYL HYDRAZIDE ETHYNES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2020-01-29 | — | — | EP | disclosed |
| EP-3297991-B1 | NOVEL AMIDOHETEROARYL AROYL HYDRAZIDE ETHYNES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2020-01-29 | — | — | EP | disclosed |
| US-10150733-B2 | Amidoheteroaryl aroyl hydrazide ethynes | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2018-12-11 | — | — | US | disclosed |
| US-20180127372-A1 | NOVEL AMIDOHETEROARYL AROYL HYDRAZIDE ETHYNES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2018-05-10 | — | — | US | disclosed |
| US-20180127372-A1 | NOVEL AMIDOHETEROARYL AROYL HYDRAZIDE ETHYNES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2018-05-10 | — | — | US | disclosed |
| EP-3297991-A1 | NOVEL AMIDOHETEROARYL AROYL HYDRAZIDE ETHYNES | Sun Pharma Advanced Research Company Ltd (IN) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016185490-A1 | NOVEL AMIDOHETEROARYL AROYL HYDRAZIDE ETHYNES | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016185490-A1 | NOVEL AMIDOHETEROARYL AROYL HYDRAZIDE ETHYNES | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2016-11-24 | — | — | WO | disclosed |
| US-9090561-B2 | Acetylenic heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-8461167-B2 | Acetylenic heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130018046-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| EP-2023933-A2 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007133560-A9 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2007133560-A2 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | ABL1 1035/4885ROR1 2716/4885LCK 4467/4885 |
| US-20130018046-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | ABL1 1035/4885ROR1 2716/4885LCK 4467/4885 |
| US-20180127372-A1 | NOVEL AMIDOHETEROARYL AROYL HYDRAZIDE ETHYNES | ERBB2, ABL1, ERBB3 | ABL1 2/4885ROR1 486/4885LCK 43/4885 |
| US-10150733-B2 | Amidoheteroaryl aroyl hydrazide ethynes | ERBB2, ABL1, ERBB3 | ABL1 2/4885ROR1 457/4885LCK 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.